All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional.

  TRANSLATE

The PsOPsA Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the PsOPsA Hub cannot guarantee the accuracy of translated content. The PsOPsA Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The PsOPsA Hub
Brought to you by Scientific Education Support

The PsOPsA Hub is an independent medical education platform. This activity is supported by an educational grant from Lilly. Funders are allowed no direct influence on our content.

View all

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

AAD 2023

Share:

Mar 24, 2023

X post image

2 May 2023

At #AAD2023, @_AprilArmstrong presented results from the phase IIb study of investigational NDI-034858 (TAK-279), an oral, once-daily TYK2 inhibitor, in people with moderate-to-severe plaque psoriasis.

Read more 👉 https://t.co/jB0gEya98Q

#psoriasis #dermtwitter

View on 

X post image

28 Apr 2023

At #AAD2023, French presented results from the phase IIb IASOS trial demonstrating the efficacy and safety of modified-release #orismilast tablets in patients with moderate-to-severe psoriasis.

Read more 👉 https://t.co/7toWO0ItMf
#psoriasis #dermtwitter

View on 

X post image

26 Apr 2023

#AAD2023 #dermtwitter https://t.co/PACCdSMjq2

View on 

X post image

21 Apr 2023

At #AAD2023, Egeberg presented data from a trial of oral roflumilast for plaque #psoriasis vs placebo. The trial met its primary endpoint of PASI75 response at Week 12.

👉 https://t.co/ncz6bdE6Fp

#dermtwitter

View on 

X post image

13 Apr 2023

Did you miss our live coverage of #AAD2023?

Click here to view our event coverage and catch up on all the major developments 👇
https://t.co/D6p67GMusp
#psoriasis #psoriaticarthritis #dermtwitter

View on 

X post image

11 Apr 2023

#AAD2023 | Congratulations @KathleenLMiao on achieving 3rd in the best poster award! Miao presented on the use of biologics in #psoriasis and #psoriaticarthritis.

#dermtwitter #dermpath

View on 

X post image

18 Mar 2023

RT @PsoriasisIFPA: What factors impact the choice of treatment?
🟪A debate-style session we did not miss here at the #AAD2023 by Drs. An…

View on 

X post image

18 Mar 2023

CONGRESS #AAD2023 | Elizabeth Kiracofe @KiracofeMD presented at the Women’s Health Therpeutic Hotline Symposium, discussing new therapeutics for #psoriasis and AD in women, highlighting that treatment is important in pregnant patients, and SDM may be key. #dermtwitter

View on 

X post image

17 Mar 2023

CONGRESS #AAD2023 | @BruceStrober presented cases to highlight management approaches for challenging clinical situations, with some tips on combination therapy and switching. #psoriasis #psoriaticarthritis #dermtwitter

View on 

X post image

17 Mar 2023

CONGRESS #AAD2023 | Kenneth Gordon discussed putting together appropriate therapeutic ladders for the treatment of #psoriasis. He highlighted the importance of understanding whether the skin, joints, or both, are more troublesome, and in listening to the patient. #dermtwitter

View on 

X post image

17 Mar 2023

CONGRESS #AAD2023 | Kristian Callis-Duffin discussed how to integrate #psoriaticarthritis into #psoriasis discussions and management plans, highlighting four steps to achieve this. #dermtwitter

View on 

X post image

17 Mar 2023

CONGRESS #AAD2023 | @_AprilArmstrong presented on comorbidities in patients with #psoriasis, focusing on uveitis, genital involvement and depression, encouraging the assessment of patients for these comorbidities. #dermtwitter

View on 

X post image

17 Mar 2023

CONGRESS #AAD2023 | George Han @ZuckerSoM presented on how to select the right biologic treatment for patients with #psoriasis. He highlights that there are multiple options and that conversations with patients are important to determine the right treatment option. #dermtwitter

View on 

X post image

17 Mar 2023

CONGRESS #AAD2023 | @_AprilArmstrong gave a great summary of JAK inhibition in #psoriasis earlier, highlighting the move away from JAK 1 inhibition, with more of a focus on TYK2 inhibition now. #dermtwitter

View on 

X post image

17 Mar 2023

CONGRESS #AAD2023 | @JosephMerolaMD presents ‘Rheumatology for the dermatologist’ reminding us how to identify inflammatory arthritis, such as #psoriaticarthritis in our patients with #psoriasis, and summarising treatment options by disease domains. #dermtwitter

View on 

X post image

17 Mar 2023

CONGRESS #AAD2023 | @JAADjournals game changers:
Richard Langley @DalhousieU presented the winning paper on reduced mortality risk with systemic #psoriasis treatment (PSOLAR) from Jan 2021 which demonstrated that biologic treatment was assoc with reduced mortality. #dermtwitter

View on 

X post image

17 Mar 2023

CONGRESS #AAD2023 | @JAADjournals game changers: Clinton Enos presented his paper on obesity and diabetes, and biologic response in #psoriasis. Obesity assoc with lower response to TNFi and IL17i, and diabetes was assoc with lower response to IL17i. #dermtwitter

View on 

X post image

16 Mar 2023

We’re here and looking forward to a great #AAD2023 #psoriasis #psoriaticarthritis #dermtwitter

View on 

X post image

16 Mar 2023

RT @IpcPs: The #IPC Global Education Day symposium at #AAD2023, Psoriasis: Using the Right Treatment in the Right Patient at the Right Time…

View on 

X post image

14 Mar 2023

The #Psoriasis and #PsoriaticArthritis Hub will be attending the #AAD2023 Annual meeting!

📅 Date: 17-21 March 2023
📍 Location: New Orleans & Online

Keep an eye on our socials for updates throughout the congress! #AAD2023 #psoriasis

#psoriaticarthritis #dermtwitter

View on 

<span>&nbsp;</span>

Please indicate your level of agreement with the following statements:

The content was clear and easy to understand

The content addressed the learning objectives

The content was relevant to my practice

I will change my clinical practice as a result of this content

More about...

AAD 2023American Academy of Dermatology

Newsletter

Subscribe to get the best content delivered to your inbox